User talk:Mlasky8/sandbox

Matt, I would approve either the Oseltamivir or Dieckmann articles. The Dieckmann does need a lot of work and better organization. Also, the Oseltamivir synthesis will need some more general information in the "introductory" section to make it more "relevant." Please be sure to read the talk pages for both articles and let me know which you want to do! Mclaughl (talk) 19:08, 17 November 2017 (UTC)[reply]

Oseltamivir total synthesis:

My plan:

My plan is going to be to highlight the total synthesis done by the Hayashi group in 2009^[1]. I intended to discuss the synthetic strategies used in each of the three one-pot operations, as well as, highlight how the procedure is suitable for large-scale production. I will also display the overall scheme for the total synthesis. I will also add more information to the introduction of Oseltamivir total synthesis to make the page more relevant because right now it does not work well.

^[2]^[3]^[4]^[5]

Mlasky8 (talk) 17:02, 21 November 2017 (UTC)[reply]

^ Ishikawa, Hayato; Suzuki, Takaki; Hayashi, Yujiro (2009). "High-yielding synthesis of the anti-influenza neuramidase inhibitor (-)-oseltamivir by three "one-pot" operations". Angewandte Chemie (International Ed. in English). 48 (7): 1304–1307. doi:10.1002/anie.200804883. ISSN 1521-3773. PMID 19123206.
^ Yarnell, Amanda. "Complexity Of Tamiflu Manufacturing May Hamper On Demand Production". http://pubs.acs.org/cen/news/83/i35/8335tamiflu1.html. 83: 22. {{cite journal}}: External link in |journal= (help)
^ MCCOY, MICHAEL (2006-03-20). "Roche Unveils Tamiflu Production Network". Chemical & Engineering News Archive. 84 (12): 10. doi:10.1021/cen-v084n012.p010a. ISSN 0009-2347.
^ Seijo, Bibiana Campos (2016-07-18). "Juno, Tamiflu, and Theranos". C&EN Global Enterprise. 94 (29): 3–3. doi:10.1021/cen-09429-editorial.
^ Magano, Javier (2009-09-09). "Synthetic Approaches to the Neuraminidase Inhibitors Zanamivir (Relenza) and Oseltamivir Phosphate (Tamiflu) for the Treatment of Influenza". Chemical Reviews. 109 (9): 4398–4438. doi:10.1021/cr800449m. ISSN 0009-2665.

[1] Ishikawa, Hayato; Suzuki, Takaki; Hayashi, Yujiro (2009). "High-yielding synthesis of the anti-influenza neuramidase inhibitor (-)-oseltamivir by three "one-pot" operations". Angewandte Chemie (International Ed. in English). 48 (7): 1304–1307. doi:10.1002/anie.200804883. ISSN 1521-3773. PMID 19123206.

[2] Yarnell, Amanda. "Complexity Of Tamiflu Manufacturing May Hamper On Demand Production". http://pubs.acs.org/cen/news/83/i35/8335tamiflu1.html. 83: 22. {{cite journal}}: External link in |journal= (help)

[3] MCCOY, MICHAEL (2006-03-20). "Roche Unveils Tamiflu Production Network". Chemical & Engineering News Archive. 84 (12): 10. doi:10.1021/cen-v084n012.p010a. ISSN 0009-2347.

[4] Seijo, Bibiana Campos (2016-07-18). "Juno, Tamiflu, and Theranos". C&EN Global Enterprise. 94 (29): 3–3. doi:10.1021/cen-09429-editorial.

[5] Magano, Javier (2009-09-09). "Synthetic Approaches to the Neuraminidase Inhibitors Zanamivir (Relenza) and Oseltamivir Phosphate (Tamiflu) for the Treatment of Influenza". Chemical Reviews. 109 (9): 4398–4438. doi:10.1021/cr800449m. ISSN 0009-2665.

[1]

[2]

[3]

[4]

[5]